About
About Huakang Biomedical Holdings Company Limited
Joyzyme Group Limited, an investment holding company, engages in the research, production, and sale of male fertility in-vitro diagnostic (IVD) reagents in the People's Republic of China. The company provides biological reagents, including male fertility IVD reagents, parasite antibody detection reagents, and Epstein-Barr virus antibody detection reagent; healthcare products and supplements; and auxiliary reproductive supplies and equipment. The company sells its products directly to hospitals and medical institutions, as well as to distributors. The company was formerly known as Huakang Biomedical Holdings Company Limited and changed its name to Joyzyme Group Limited in January 2026. Joyzyme Group Limited was founded in 1992 and is based in Tsim Sha Tsui, Hong Kong.
Visit company website
5 years, 4 months ago
Huakang Biomedical Holdings Company Limited is currently in a long term uptrend where the price is trading 24.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Huakang Biomedical Holdings Company Limited's total revenue rose by 11.5% to $8M since the same quarter in the previous year.
Its net income has dropped by 150.6% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.8% to $-4M since the same quarter in the previous year.
Based on the above factors, Huakang Biomedical Holdings Company Limited gets an overall score of 3/5.